Longitudinal Analysis of Plasma Proteomic Alterations After BNT162b2 COVID-19 Booster Vaccination in Qatar - Takeaways - MDSpire

Longitudinal Analysis of Plasma Proteomic Alterations After BNT162b2 COVID-19 Booster Vaccination in Qatar

  • By

  • Sana Bentebbal

  • Ahmed Zaqout

  • Bakhita Meqbel

  • Ilham Bensmail

  • Abdullah Aldushain

  • Alberto de la Fuente

  • Remy Thomas

  • Adviti Naik

  • Hibah Shaath

  • Neyla S. Al-Akl

  • Abdi Adam

  • Houda Y. A. Moussa

  • Kyung C. Shin

  • Rowaida Z. Taha

  • Mohammed Abukhattab

  • Muna A. Al-Maslamani

  • Nehad M. Alajez

  • Abdelilah Arredouani

  • Yongsoo Park

  • Sara A. Abdulla

  • Omar M. A. El-Agnaf

  • Houari B. Abdesselem

  • Ali S. Omrani

  • Julie Decock

  • April 24, 2026

  • 0 min

Share

  • 1

    This study analyzed plasma proteomic changes after the BNT162b2 COVID-19 booster vaccination over a 6-month period.

  • 2

    Infection-naïve individuals exhibited significant alterations in eleven proteins at 3 months and eight proteins at 6 months post-booster.

  • 3

    Key proteins PARP-1 and MMP-7 showed consistent upregulation and downregulation, respectively, across both infection-naïve and previously infected individuals.

  • 4

    Longitudinal profiling revealed dysregulation of inflammatory proteins, indicating ongoing immune responses post-booster vaccination.

  • 5

    The findings highlight the importance of monitoring proteomic responses to optimize booster vaccination strategies and resource allocation.

Original Source(s)

Longitudinal Analysis of Plasma Proteomic Alterations After BNT162b2 COVID-19 Booster Vaccination in Qatar

  • by Sana Bentebbal, Ahmed Zaqout, Bakhita Meqbel, Ilham Bensmail, Abdullah Aldushain, Alberto de la Fuente, Remy Thomas, Adviti Naik, Hibah Shaath, Neyla S. Al-Akl, Abdi Adam, Houda Y. A. Moussa, Kyung C. Shin, Rowaida Z. Taha, Mohammed Abukhattab, Muna A. Al-Maslamani, Nehad M. Alajez, Abdelilah Arredouani, Yongsoo Park, Sara A. Abdulla, Omar M. A. El-Agnaf, Houari B. Abdesselem, Ali S. Omrani, Julie Decock

  • April 24, 2026

Related Content

Effectiveness of Telemedicine vs Face-to-Face Consultation in Fighting COVID-19: Retrospective Cohort Study of Adult Patients With COVID-19 in a Primary Care Setting

The latest developments on Ebola, hepatitis B, long Covid

Case Report: Successful treatment of recurrent COVID-19 with intravenous immunoglobulin in a patient with rituximab-induced B-cell depletion and restoration of Fc-mediated effector functions